Longeveron Inc. (LGVN)
NASDAQ: LGVN
· Real-Time Price · USD
1.57
-0.11 (-6.55%)
At close: May 01, 2025, 3:59 PM
1.55
-1.59%
After-hours: May 01, 2025, 07:07 PM EDT
-6.55% (1D)
| Bid | 1.55 |
| Market Cap | 23.56M |
| Revenue (ttm) | 2.39M |
| Net Income (ttm) | -15.97M |
| EPS (ttm) | -2.62 |
| PE Ratio (ttm) | -0.6 |
| Forward PE | -1.29 |
| Analyst | Buy |
| Ask | 1.65 |
| Volume | 232,579 |
| Avg. Volume (20D) | 252,124 |
| Open | 1.77 |
| Previous Close | 1.68 |
| Day's Range | 1.49 - 1.65 |
| 52-Week Range | 0.77 - 6.40 |
| Beta | 0.38 |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, a...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2021
Employees 25
Stock Exchange NASDAQ
Ticker Symbol LGVN
Website https://www.longeveron.com
Analyst Forecast
According to 3 analyst ratings, the average rating for LGVN stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 534.92% from the latest price.
Stock Forecasts2 months ago
-0.65%
Longeveron shares are trading higher after the com...
Unlock content with
Pro Subscription
9 months ago
+0.87%
Longeveron shares are trading higher after the company announced study results from the CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer's disease, meeting its key objectives to advance data supporting a favorable benefit/risk profile.
